AXSM News and Press, Axsome Therapeutics Inc. From 11/09/22

NEW YORK, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executiv...

Axsome Therapeutics ( NASDAQ: AXSM ) rose sharply on Tuesday as Cantor Fitzgerald noted favorable early trends in the rollout of the company’s new additions to the portfolio, sleep disorder therapy Sunosi and depression treatment Auvelity. Axsome ( AXSM ) acquired...

Axsome Therapeutics (NASDAQ: AXSM) , a central nervous system disorder specialist, is having a good day today. Specifically, the drugmaker's shares are up by a healthy 12.2% on heavy volume as of 1:02 p.m. ET Tuesday afternoon. If this latest move holds, Axsome's shares will end the...

As a stock smack dab in the midst of the ever up-and-down biotech sector, Axsome Therapeutics (NASDAQ: AXSM) has certainly had some good trading days. Alas, Monday wasn't one of them, as investors traded the company's shares down modestly. This was on the back of the company's lates...

Start Time: 08:00 End Time: 08:48 Axsome Therapeutics, Inc. (AXSM) Q3 2022 Earnings Conference Call November 07, 2022, 08:00 AM ET Company Participants Herriot Tabuteau - Chairman and CEO Nick Pizzie - CFO Mark Jacobson - COO Lori Englebert - EVP, Com...

Image source: The Motley Fool. Axsome Therapeutics (NASDAQ: AXSM) Q3 2022 Earnings Call Nov 07, 2022 , 8:00 a.m. ET Operator Continue reading For further details see: Axsome Therapeutics (AXSM) Q3 2022 Earnings Call Transcript

Axsome Therapeutics press release ( NASDAQ: AXSM ): Q3 GAAP EPS of -$1.07 beats by $0.02 . Revenue of $16.8M misses by $0.26M . Cash and cash equivalents totaled $227.5 million at September 30, 2022, compared to $86.5 million at December 31, 2021. During the qu...

Sunosi® third quarter U.S. net sales of $16.8 million Auvelity™ launched and available in U.S. pharmacies SHARP study results announced demonstrating statistically significant improvement in cognitive function with Sunosi versus placebo ADVANCE-2 tria...

Axsome Therapeutics ( NASDAQ: AXSM ) is scheduled to announce Q3 earnings results on Monday, November 7th, before market open. The consensus EPS Estimate is -$1.10 (-18.3% Y/Y) and the consensus Revenue Estimate is $17.06M Over the last 1 year, AXSM has beaten EPS es...

The end of the year is right around the corner. But this time of year actually is a beginning for certain healthcare stocks. That's because important share-performance catalysts and/or revenue opportunities lie just ahead. And that's why these players make great buys in November. CRIS...